News of Note—Merck Big Data; AbbVie JAK1 win; Bayer, Vanderbilt deal

Deals for European pharmas as AbbVie gets RA data win

> Merck KGaA is joining forces with non-profit Project Data Sphere as the pair eye working on a new, global cancer Big Data alliance. Release

> AbbVie has posted positive top-line results from the late-stage test of upadacitinib, its investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis. The candidate hit its primary and secondary endpoints, but two deaths hit the company's sharesJefferies however say: "The deaths were considered by investigators to have no reasonable possibility of being related to upadacitinib at the time of initial reporting.". Statement

> German pharma Bayer and the Vanderbilt University Medical Center have penned a five-year R&D alliance aimed at finding new therapies against kidney diseases. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

 

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.